Angiotensin receptor-neprilysin inhibitor (ARNi): Clinical studies on a new class of drugs

Int J Cardiol. 2017 Jan 1:226:136-140. doi: 10.1016/j.ijcard.2016.06.083. Epub 2016 Jun 23.

Abstract

Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart failure with both preserved (HFpEF) and reduced ejection fraction (HFrEF). In this review, the evidences in patients with HFpEF and HFrEF are summarized, including the results of more recent studies.

Keywords: ARNi; Angiotensin receptor–neprilysin inhibitor; Heart failure; LCZ696.

Publication types

  • Review

MeSH terms

  • Aminobutyrates / pharmacology
  • Aminobutyrates / therapeutic use*
  • Angiotensin II Type 1 Receptor Blockers / pharmacology
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin Receptor Antagonists / pharmacology
  • Angiotensin Receptor Antagonists / therapeutic use*
  • Biphenyl Compounds
  • Clinical Trials as Topic / methods
  • Drug Combinations
  • Heart Failure / drug therapy*
  • Heart Failure / physiopathology
  • Humans
  • Neprilysin / antagonists & inhibitors*
  • Neprilysin / metabolism
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Valsartan

Substances

  • Aminobutyrates
  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin Receptor Antagonists
  • Biphenyl Compounds
  • Drug Combinations
  • Tetrazoles
  • Valsartan
  • Neprilysin
  • sacubitril and valsartan sodium hydrate drug combination